Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Stroke ; 52(5): e117-e130, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33878892
2.
J Stroke Cerebrovasc Dis ; 29(12): 105353, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33039770

RESUMEN

Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Neurological manifestations related to COVID-19, including acute ischemic Stroke (AIS), have been reported in recent studies. In most of these, the patients are older, have multiple co-morbidities as risk factors for AIS and have developed a severe respiratory illness. Herein, we report a 36-year-old man with no significant past medical history who recently recovered from a mild COVID-19 infection and presented with unusual pattern of arterial macrothrombosis causing AIS. When the AIS happened, he had no COVID-19 related symptoms, had two negative screening tests for the infection and his chest CT was unremarkable.


Asunto(s)
Isquemia Encefálica/etiología , COVID-19/complicaciones , Estenosis Carotídea/etiología , Trombosis Intracraneal/etiología , Accidente Cerebrovascular/etiología , Adulto , Factores de Edad , Anticoagulantes/administración & dosificación , Isquemia Encefálica/diagnóstico por imagen , Isquemia Encefálica/terapia , COVID-19/diagnóstico , Estenosis Carotídea/diagnóstico por imagen , Estenosis Carotídea/terapia , Heparina/administración & dosificación , Humanos , Trombosis Intracraneal/diagnóstico por imagen , Trombosis Intracraneal/terapia , Masculino , Accidente Cerebrovascular/diagnóstico por imagen , Accidente Cerebrovascular/terapia , Trombectomía , Factores de Tiempo , Resultado del Tratamiento
3.
Neurosurg Focus ; 42(4): E4, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28366053

RESUMEN

Despite the success of numerous neuroprotective strategies in animal and preclinical stroke models, none have effectively translated to clinical medicine. A multitude of influences are likely responsible. Two such factors are inefficient recanalization strategies for large vessel occlusions and suboptimal delivery methods/platforms for neuroprotective agents. The recent endovascular stroke trials have established a new paradigm for large vessel stroke treatment. The associated advent of advanced mechanical revascularization devices and new stroke technologies help address each of these existing gaps. A strategy combining effective endovascular revascularization with administration of neuroprotective therapies is now practical and could have additive, if not synergistic, effects. This review outlines past and current neuroprotective strategies assessed in acute stroke trials. The discussion focuses on delivery platforms and their potential applicability to endovascular stoke treatment.


Asunto(s)
Sistemas de Liberación de Medicamentos , Fármacos Neuroprotectores/administración & dosificación , Accidente Cerebrovascular/terapia , Trombectomía/métodos , Animales , Isquemia Encefálica/complicaciones , Servicios Médicos de Urgencia , Humanos , Accidente Cerebrovascular/etiología
4.
Neurosurg Focus ; 37(1 Suppl): 1, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24983724

RESUMEN

Type 1 spinal dural arteriovenous fistula (dAVF) constitute the vast majority of all spinal vascular malformations. Here we present the case of a 71-year-old male with progressive myelopathy, lower-extremity weakness and numbness, and urinary incontinence. MRI imaging of the thoracic spine demonstrated cord edema, and catheter spinal angiography confirmed a type 1 spinal dAVF. The fistula was supplied by small dural branches of the left L-2 segmental artery. Angiographic cure was achieved with a one-stage procedure in which coils were used to occlude the distal segmental vessels, followed by balloon-assisted embolization with Onyx. The video can be found here: http://youtu.be/8aehJbueH0U .


Asunto(s)
Oclusión con Balón/métodos , Malformaciones Vasculares del Sistema Nervioso Central/cirugía , Enfermedades de la Columna Vertebral/cirugía , Anciano , Angiografía , Malformaciones Vasculares del Sistema Nervioso Central/complicaciones , Malformaciones Vasculares del Sistema Nervioso Central/diagnóstico , Humanos , Imagen por Resonancia Magnética , Masculino , Enfermedades de la Columna Vertebral/complicaciones , Enfermedades de la Columna Vertebral/diagnóstico
5.
Neurosurg Focus ; 37(1 Suppl): 1, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24983725

RESUMEN

Open surgical disconnection has long been the treatment of choice for dural arteriovenous fistulas (dAVFs) of the anterior cranial fossa. However, advanced patient age and the presence of medical comorbidities can substantially increase the risk of craniotomy and favor a less invasive endovascular approach. Optimal positioning within the distal ophthalmic artery, beyond the origin of the central retinal branch, is achievable using current microcatheter technology and embolic materials. Here we present the case of an 88-year-old female with an incidentally discovered dAVF of the anterior cranial fossa. Angiographic cure was achieved with one-stage Onyx embolization. The video can be found here: http://youtu.be/KVE0fUIECQM .


Asunto(s)
Malformaciones Vasculares del Sistema Nervioso Central/cirugía , Fosa Craneal Anterior/cirugía , Embolización Terapéutica/métodos , Anciano de 80 o más Años , Malformaciones Vasculares del Sistema Nervioso Central/complicaciones , Angiografía Cerebral , Embolización Terapéutica/instrumentación , Femenino , Humanos , Imagen por Resonancia Magnética , Arteria Oftálmica/cirugía , Polivinilos , Resultado del Tratamiento , Trastornos de la Visión/etiología
6.
JAMA Netw Open ; 5(10): e2238154, 2022 10 03.
Artículo en Inglés | MEDLINE | ID: mdl-36279137

RESUMEN

Importance: Randomized clinical trials have shown the efficacy of endovascular therapy (EVT) for acute large vessel occlusion strokes. The benefit of EVT in acute stroke with distal, medium vessel occlusion (DMVO) remains unclear. Objective: To examine the efficacy and safety outcomes associated with EVT in patients with primary DMVO stroke when compared with a control cohort treated with medical management (MM) alone. Design, Setting, and Participants: This multicenter, retrospective cohort study pooled data from patients who had an acute stroke and a primary anterior circulation emergency DMVO, defined as any segment of the anterior cerebral artery (ACA) or distal middle cerebral artery, between January 1, 2015, and December 31, 2019. Those with a concomitant proximal occlusion were excluded. Outcomes were compared between the 2 treatment groups using propensity score methods. Data analysis was performed from March to June 2021. Exposures: Patients were divided into EVT and MM groups. Main Outcomes and Measures: Main efficacy outcomes included 3-month functional independence (modified Rankin Scale [mRS] scores, 0-2) and 3-month excellent outcome (mRS scores, 0-1). Safety outcomes included 3-month mortality and symptomatic intracranial hemorrhage. Results: A total of 286 patients with DMVO were evaluated, including 156 treated with EVT (mean [SD] age, 66.7 [13.7] years; 90 men [57.6%]; median National Institute of Health Stroke Scale [NIHSS] score, 13.5 [IQR, 8.5-18.5]; intravenous tissue plasminogen activator [IV tPA] use, 75 [49.7%]; ACA involvement, 49 [31.4%]) and 130 treated with medical management (mean [SD] age, 69.8 [14.9] years; 62 men [47.7%]; median NIHSS score, 7.0 [IQR, 4.0-14.0], IV tPA use, 58 [44.6%]; ACA involvement, 31 [24.0%]). There was no difference in the unadjusted rate of 3-month functional independence in the EVT vs MM groups (151 [51.7%] vs 124 [50.0%]; P = .78), excellent outcome (151 [38.4%] vs 123 [31.7%]; P = .25), or mortality (139 [18.7%] vs 106 [11.3%]; P = .15). The rate of symptomatic intracranial hemorrhage was similar in the EVT vs MM groups (weighted: 4.0% vs 3.1%; P = .90). In inverse probability of treatment weighting propensity analyses, there was no significant difference between groups for functional independence (adjusted odds ratio [aOR], 1.36; 95% CI, 0.84-2.19; P = .20) or mortality (aOR, 1.24; 95% CI, 0.63-2.43; P = .53), whereas the EVT group had higher odds of an excellent outcome (mRS scores, 0-1) at 3 months (aOR, 1.71; 95% CI, 1.02-2.87; P = .04). Conclusions and Relevance: The findings of this multicenter cohort study suggest that EVT may be considered for selected patients with ACA or distal middle cerebral artery strokes. Further larger randomized investigation regarding the risk-benefit ratio for DMVO treatment is indicated.


Asunto(s)
Procedimientos Endovasculares , Accidente Cerebrovascular , Masculino , Humanos , Anciano , Activador de Tejido Plasminógeno/uso terapéutico , Estudios Retrospectivos , Estudios de Cohortes , Procedimientos Endovasculares/métodos , Resultado del Tratamiento , Accidente Cerebrovascular/etiología , Hemorragias Intracraneales
7.
Int J Stroke ; 7(4): 293-7, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22151911

RESUMEN

BACKGROUND: The influence of lesion size and laterality on each component of the National Institutes of Health Stroke Scale has not been delineated. The objective of this study was to use perfusion-weighted imaging to characterize the association of ischaemic volume and laterality on each component item and the total score of the 10 s. Ordinal regression was used to clarify the relationship between ischaemic volume, laterality, and

Asunto(s)
Isquemia Encefálica/patología , Lateralidad Funcional/fisiología , Accidente Cerebrovascular/patología , Anciano , Isquemia Encefálica/fisiopatología , Femenino , Humanos , Angiografía por Resonancia Magnética , Masculino , Persona de Mediana Edad , Debilidad Muscular/etiología , Debilidad Muscular/patología , Estudios Prospectivos , Trastornos Psicomotores/etiología , Trastornos Psicomotores/patología , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/fisiopatología
8.
J Neurol Sci ; 313(1-2): 142-6, 2012 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-21945462

RESUMEN

BACKGROUND: Early disruption of the blood-brain barrier (BBB) due to severe ischemia can be detected by MRI T2* permeability imaging. In middle cerebral artery (MCA) infarction, pretreatment T2* permeability derangements have been found in 22% of patients and are powerful predictors of hemorrhagic transformation after revascularization therapy. The frequency, clinical correlates, and relation to hemorrhagic transformation of permeability derangements in posterior circulation have not been previously explored, and may differ as ischemia volume and collateral status are different between vertebrobasilar and MCA infarcts. METHODS: We analyzed clinical and pretreatment MRI data on consecutive patients undergoing recanalization therapy for acute vertebrobasilar ischemia at a medical center November 2001 through September 2009. Pretreatment MRI permeability images were derived from perfusion source imaging acquisitions. Permeability abnormality was detected as persisting increased signal intensity at later time points in perfusion MRI acquisition, indicating local accumulation of contrast caused by BBB leakage. RESULTS: Among the 14 patients meeting study entry criteria, mean age was 71.1 years and median pretreatment NIHSS was 20.5. Permeability imaging abnormality was present in 1 of the 14 patients (7%). Among 14 patients, post-treatment parenchymal hematoma occurred in one and more minor degrees of hemorrhagic transformation in four. The one patient with pretreatment permeability abnormality was the patient to develop post-treatment parenchymal hematoma (Fisher's exact test, P=0.07). CONCLUSION: Pretreatment permeability abnormality, an indicator of BBB derangements, is an infrequent finding in acute posterior circulation ischemic stroke and may be associated with an increased risk of parenchymal hematoma development undergoing recanalization therapy.


Asunto(s)
Barrera Hematoencefálica/metabolismo , Permeabilidad Capilar/fisiología , Hemorragia Cerebral/metabolismo , Accidente Cerebrovascular/metabolismo , Insuficiencia Vertebrobasilar/metabolismo , Anciano , Anciano de 80 o más Años , Barrera Hematoencefálica/patología , Isquemia Encefálica/metabolismo , Isquemia Encefálica/patología , Hemorragia Cerebral/patología , Femenino , Humanos , Ataque Isquémico Transitorio/metabolismo , Ataque Isquémico Transitorio/patología , Masculino , Persona de Mediana Edad , Accidente Cerebrovascular/patología , Insuficiencia Vertebrobasilar/patología
9.
World Neurosurg ; 76(6 Suppl): S16-23, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22182267

RESUMEN

OBJECTIVE: Intracranial large-vessel ischemia is associated with poor clinical outcome and increased mortality. Early reperfusion of ischemic tissue remains the goal of treatment of stroke. Intravenous tissue plasminogen activator (IV tPA) has been shown to improve clinical outcomes for patients who experience ischemic stroke, but it has been shown to be less efficacious for large-vessel occlusions. Mechanical clot extraction provides a therapeutic option for those who are ineligible for, or who do not respond to, conventional ischemic stroke treatment. METHODS: We reviewed the initial studies of the Merci Retriever and Penumbra System for mechanical clot extraction. Baseline patient characteristics, as well as revascularization rates and clinical outcome, were examined. RESULTS: Baseline National Institutes of Health Stroke Scale scores were greater than those observed in previous IV tPA studies, consistent with large-vessel occlusion. Successful recanalization occurred more frequently than with IV tPA and was associated with improved clinical outcome and mortality. Symptomatic intracranial hemorrhage and mortality rates were greater than those seen with IV tPA. CONCLUSIONS: Mechanical clot extraction can be performed safely in patients with large-vessel occlusions, and successful recanalization resulted in better clinical outcomes than those without. Mechanical thrombectomy provides a therapeutic option for ischemic stroke patients who are ineligible for, or who do not respond to, IV thrombolytics. Further studies, including randomized clinical trials, are needed to validate these findings.


Asunto(s)
Isquemia Encefálica/cirugía , Retracción del Coagulo , Accidente Cerebrovascular/cirugía , Trombectomía/métodos , Tromboembolia/cirugía , Isquemia Encefálica/complicaciones , Isquemia Encefálica/mortalidad , Revascularización Cerebral , Embolectomía , Humanos , Activadores Plasminogénicos/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/mortalidad , Tromboembolia/complicaciones , Terapia Trombolítica , Activador de Tejido Plasminógeno/uso terapéutico , Resultado del Tratamiento , Estados Unidos , United States Food and Drug Administration
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA